BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. rs2476601, FXYD4, Fatty acid metabolic process, Leukemia, Lymphocyte, Valproic acid)
Bookmark Forward

QuickView for LAG3 (gene)


Body Atlas

Most Correlated Tissues

  1. T Lymphocyte (CD8+) of peripheral blood
  2. Natural killer cell of peripheral blood
  3. T Lymphocyte (regulatory) of peripheral blood
  4. Appendix
  5. T Lymphocyte (CD4+) of peripheral blood
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Meningitis
  2. Viral infections of the central nervous system
  3. Malaria
  4. Epstein-Barr virus disease
  5. Enchondromatosis
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. grass pollen extract, alum-adsorbed
  2. OVA-8
  3. IL2 protein, human
  4. 5'PPP-RNA
  5. Antibodies
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. Sle1c
  2. PELP1
  3. SPOP
  4. ARHGAP5
  5. PSEN1
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. LAG3 (CD223) and autoimmunity: Emerging evidence.
  2. LAG3 (CD223) as a cancer immunotherapy target.
  3. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach.
  4. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immun…
  5. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. LAG3 PET Imaging in Advanced Solid Tumors
  2. Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic …
  3. Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanom…
  4. Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC
  5. Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prio…
Explore Clinical Trials Results
  • Copyright © 2021 Illumina Inc. All rights reserved.